Analysis of the association between adverse events and outcome in patients receiving a programmed death protein-1 or programmed death ligand-1 antibody.
作者信息
García-Aranda Marilina, Redondo Maximino
机构信息
Research Unit, Hospital Costa del Sol, Marbella, Málaga, Spain; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), ISCIII, Madrid, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; Surgery, Biochemistry and Immunology Department, School of Medicine, University of Málaga, Málaga, Spain.
出版信息
Chin Clin Oncol. 2020 Aug;9(4):57. doi: 10.21037/cco.2020.03.01. Epub 2020 Mar 4.
PMID:32156121
Abstract
摘要
相似文献
1
Analysis of the association between adverse events and outcome in patients receiving a programmed death protein-1 or programmed death ligand-1 antibody.接受程序性死亡蛋白-1或程序性死亡配体-1抗体治疗患者的不良事件与预后之间的关联分析
Chin Clin Oncol. 2020 Aug;9(4):57. doi: 10.21037/cco.2020.03.01. Epub 2020 Mar 4.
2
[The predicive biomarkers of programmed death receptor-l/ligand antibodes in the treatement of non-small-cell lung cancer].[程序性死亡受体-1/配体抗体治疗非小细胞肺癌的预测生物标志物]
Zhonghua Jie He He Hu Xi Za Zhi. 2018 Oct 12;41(10):799-803. doi: 10.3760/cma.j.issn.1001-0939.2018.10.010.
3
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.免疫相关不良事件与非小细胞肺癌的程序性细胞死亡蛋白-1 和程序性死亡配体 1 抑制剂相关：PRISMA 系统评价和荟萃分析。
BMC Cancer. 2019 Jun 10;19(1):558. doi: 10.1186/s12885-019-5701-6.
4
Programmed death of chemotherapy in non-small-cell lung cancer?非小细胞肺癌化疗中的程序性死亡？
Lancet. 2017 Jan 21;389(10066):227-228. doi: 10.1016/S0140-6736(16)32535-1. Epub 2016 Dec 13.
5
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.肿瘤表达及作为生物标志物在伴有预先存在的间质性肺病的晚期非小细胞肺癌患者中程序性死亡配体 1 的作用。
Med Oncol. 2019 Apr 27;36(6):49. doi: 10.1007/s12032-019-1274-0.
6
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.利用 22C3 抗程序性死亡配体 1 抗体检测非小细胞肺癌患者细胞学样本中的程序性死亡配体 1 表达。
Cancer Cytopathol. 2018 Apr;126(4):264-274. doi: 10.1002/cncy.21977. Epub 2018 Feb 7.
7
Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer.将程序性死亡-1抑制剂应用于非小细胞肺癌的一线治疗
J Clin Oncol. 2016 Sep 1;34(25):2953-5. doi: 10.1200/JCO.2016.68.1205. Epub 2016 Jul 5.
8
Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.程序性细胞死亡蛋白1配体1异质性在非小细胞肺癌患者接受免疫治疗选择中的意义
Clin Pharmacol Ther. 2016 Sep;100(3):220-2. doi: 10.1002/cpt.360. Epub 2016 May 3.
9
Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.使用抗程序性细胞死亡蛋白1和抗程序性细胞死亡配体1药物治疗肺癌期间的毛发再色素沉着
JAMA Dermatol. 2017 Nov 1;153(11):1162-1165. doi: 10.1001/jamadermatol.2017.2106.
10
Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.肿瘤浸润淋巴细胞中程序性死亡受体 1 表达与非小细胞肺癌中程序性死亡配体 1 表达的相关性。
Arch Pathol Lab Med. 2018 Nov;142(11):1388-1393. doi: 10.5858/arpa.2017-0516-OA. Epub 2018 Feb 12.
引用本文的文献
1
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside.免疫检查点抑制剂相关性肌炎：从生物学到临床。
Int J Mol Sci. 2020 Apr 26;21(9):3054. doi: 10.3390/ijms21093054.
Zotero 插件